Clover Biopharmaceuticals snaps up $230m Series C
Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing.
Clover Biopharmaceuticals, a global clinical-stage biotechnology company, has secured $230 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination